SCHEMBL371092

SCHEMBL371092

CCC1OCc2sc(N)nc2-c2cn(Cc3ccc(OC)cc3)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 8/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
MPI P34949 1/20 0.39
DRD2 P14416 1/20 0.36
KCNH2 Q12809 1/20 0.36
AADAT Q8N5Z0 1/20 0.36
LMNA P02545 2/20 0.33
GAA P10253 1/20 0.33
POLB P06746 1/20 0.33
LTA4H P09960 1/20 0.32
ACHE P22303 1/20 0.32
HPGD P15428 1/20 0.31
PDE5A O76074 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
PDE8B O95263 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368608 0.89 ADORA1 (0.40) ADORA1ALDH1A1KDM4EMAPTMPI
SCHEMBL369588 0.80 GRM4 (0.40) ALDH1A1KDM4EGAAACHENPC1
SCHEMBL371000 0.80 KDM4E (0.45) ADORA1ALDH1A1KDM4EMAPTMPI
SCHEMBL6837211 0.80 ADORA1 (0.42) ADORA1ALDH1A1KDM4EMAPTMPI
SCHEMBL369977 0.79 KDM4E (0.44) ADORA1ALDH1A1KDM4EMAPTMPI
SCHEMBL370449 0.77 MAPT (0.42) ADORA1ALDH1A1KDM4EMAPTMPI
SCHEMBL6837226 0.75 DRD2 (0.36) ADORA1ALDH1A1KDM4EMAPTMPI
SCHEMBL15260941 0.75 AADAT (0.42) ADORA1ALDH1A1KDM4EMAPTMPI
SCHEMBL6837318 0.75 ALDH1A1 (0.47) ADORA1ALDH1A1KDM4EMAPTMPI
SCHEMBL369640 0.74 KDM4E (0.49) ADORA1ALDH1A1KDM4EMAPTMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 ADORA1 152/4885ALDH1A1 3331/4885KDM4E 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.